Standard-Setting Bodies Engage Russia - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Standard-Setting Bodies Engage Russia
As the pharmaceutical industry moves further into Central and Eastern Europe and the Commonwealth of Independent States, several standard-setting and regulatory bodies are also increasing collaboration in the region, particularly in Russia.


Pharmaceutical Technology
Volume 33, Issue 10

As the pharmaceutical industry moves further into Central and Eastern Europe and the Commonwealth of Independent States, several standard-setting and regulatory bodies are also increasing collaboration in the region, particularly in Russia.

USP. In April 2009, the United States Pharmacopeial (USP) Convention signed a Memorandum of Understanding (MOU) with the Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (Roszdravnadzor, the US FDA equivalent). In addition to implementing the use of the first Russian translation of the US Pharmacopeia–National Formulary, the agreement calls for, among other things, organizing joint annual scientific meetings, sharing information—especially during incidents of contamination or accidental adulteration of medicines, developing additional reference materials, and the consideration of a third-party program for auditing active pharmaceutical ingredients manufacturers.

"USP is very pleased to cooperate with Roszdravnadzor on improving the quality of drugs in the United States and Russia," says USP CEO Roger Williams. "Both parties are committed to the relationship and collaborative work, which impacts patients in our respective countries and worldwide who rely on quality medicines."

Since signing the MOU in April 2009, Roszdravnadzor was elected to the USP Convention—a governing body that guides the organization's work—and is exploring scientific exchange opportunities with USP, including a staff exchange in 2010. An updated version of the USP-NF Russian translation is also in the works with an expected 2010 release.

IPEC. The International Pharmaceutical Excipients Council of Europe welcomed its first Russian member company, Pharmstandard, in July 2009. Pharmstandard (Moscow), the leading domestic pharmaceutical company in Russia in terms of sales (totaling RUB 14.3 million in 2008; $456,000) according to the Pharmexpert Marketing Research Center. Pharmstandard has manufacturing facilities in Kursk, Ufa, Tomsk, and Nizhny Novgorod.

PDA. In August, the Parenteral Drug Association (PDA) formed a partnership with Eli Lilly (Indianapolis) and the Purdue Research Park-based Chao Center for Industrial Pharmacy & Contract Manufacturing to help train the Russian Inspectorate on current good manufacturing practices. The program is aimed at advancing Russia's manufacturing and quality control standards and increasing international dialogue between Rozdravnadzor and other regulators with regard to pharmaceutical regulations and inspections, according to an Aug. 3, 2009 Purdue release.

For more on this topic, see the special report "Emerging Markets of the East" and the online exclusives "Multinational Firms Stake Claims" and "CROs and CMOs Go Further East"

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here